Browsing: Markets

Spain Producer Prices Decline Most Since 1975

(RTTNews) – Spain’s producer prices declined at a record pace in May, data from the statistical office INE showed on Thursday.
The producer prices index fell 8.7 percent year-on-year in May, following an 8.4 percent decline in April. This was the slowest since the series began in January 1975.
Excluding energy, producer price decreased 0.9 percent in May, following a 0.5 percent fall in the previous month.
Prices for energy declined 24.7 percent annually in May and intermediate goods prices decreased 3.5 percent.
Meanwhile, consumer goods prices rose 0.9 percent and prices of capital goods increased 0.8 percent.
On a monthly basis, producer prices decreased 0.2 percent in May, following a 3.0 percent decline in the prior month.

Moderna, Catalent Collaborate For Manufacturing Of COVID-19 Vaccine Candidate

(RTTNews) – Moderna Inc. (MRNA) and Catalent Inc. (CTLT) said that they have collaborated for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Indiana.
As part of the deal, Catalent will provide vial filling and packaging capacity, as well as additional staffing required for around the clock manufacturing operations at the site to support production of an initial 100 million doses of the vaccine candidate intended to supply the U.S. market starting in the third quarter of 2020.
The companies are in discussions to secure fill-finish capacity for continued production of hundreds of millions of additional doses.
Catalent will also provide clinical supply services from its facilities in Philadelphia, Pennsylvania, including packaging and labeling, as well as storage and distribution to support Moderna’s Phase 3 clinical study for this candidate.

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath® Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review. 
“This validation study for myPath Melanoma demonstrates the ability of the test to accurately classify lesions which are ruled indeterminate by an expert dermatopathologist,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Importantly, this accuracy was linked to the gold standard endpoint of real world clinical outcomes demonstrating the accuracy of the myPath Melanoma test result for patients and physicians concerned about this deadly cancer.”
The study evaluated 181 skin lesions of which 125 were ruled indeterminate by at least one of seven blinded dermatopathologists who reviewed the samples. The samples were linked to known real world outcomes with 43 percent of samples representing malignant melanomas. Importantly, myPath Melanoma demonstrated 90.4 percent sensitivity and 95.5 percent specificity in the indeterminate sample cohort and 93.8 percent sensitivity and 96.2 percent specificity when evaluating the entire sample cohort. This data is consistent with multiple other clinical validation studies for myPath Melanoma which have demonstrated the ability of the test to delineate melanoma from benign skin lesions with high diagnostic accuracy.
About MelanomaAccording to the American Cancer Society, approximately 100,350 Americans are expected to be diagnosed with melanoma this year.  Early and accurate diagnosis of melanoma is critical for long-term survival. 
About Myriad myPath® Melanoma Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The test measures the expression of 23 genes and accurately distinguishes melanoma from benign nevi.  For more information visit:

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company’s website:
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements.  These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.  All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Media Contact:
Jared Maxwell
Investor Contact:
Scott Gleason
(801) 505-5027
(801) 584-1143

Global stocks wobble as coronavirus cases surge and a 'harsh dose of COVID-19 reality' hits investors

Stocks wobbled on Thursday as investors were spooked by a “stunning” rise in coronavirus cases and the International Monetary Fund’s further diminished world economic outlook this year.
US stocks are set to open slightly down as futures tied to major indexes fell only as much as 0.3%.
“The harsh dose of Covid-19 reality capped a lousy night for the US, and by association, world markets,” a senior Asia Pacific market analyst at OANDA said.
Visit Business Insider’s homepage for more stories.
Global stocks were shaky on Thursday as investors weighed the possibility of a rapid rise in US coronavirus cases leading to reimposed shutdowns, and a bleak economic outlook from the IMF.
On Wednesday, the US outpaced its highest single-day total of new infections by over 36,000. The bulk of new cases emerged from Florida, California, and Texas.
Futures tied to the S&P 500 fell 0.3%. European indexes reversed early losses as the pan-continental Euro Stoxx 50 rose 0.3%, and Germany’s DAX rose 0.4%.

Case counts also rose abroad in New Zealand, Australia, Germany, South Korea, and China adding to a “harsh dose of COVID-19 reality” that capped the previous day’s global stock market decline, said Jeffrey Halley, a senior market analyst at OANDA. 
Read more: Morgan Stanley handpicks 10 stocks to buy now for the richest profits as travel and outdoor activities transform in the post-pandemic world
Investor fears were also fueled by the IMF projecting an even deeper global recession than expected in April, with global gross domestic product expected to contract 4.9% this year. That is down from its previous forecast of -3% in April.
One analyst said the rapid rise in new infections in the US is both “stunning and unsurprising.”
“It didn’t take a genius to foresee this happening, with the country headed up by a leader who puts winning elections first, the economy second and, at best, human life a distant third,” Connor Campbell, a financial analyst at SpreadEx, said in a note.

What remains doubtful is whether a stricter lockdown will be reimposed as President Trump may not be keen to double-down on the economic toll caused by the first round of restrictions, Campbell said. 
Read more: Aram Green has crushed 99% of his stock-picking peers over the last 5 years. He details his approach for finding hidden gems – and shares 6 underappreciated stocks poised to dominate in the future
Here’s the market roundup as of  10.50 a.m in London (5.50 a.m. ET):
Asian indexes were mostly down with China’s Shanghai Composite flat, Hong Kong’s Hang Seng down 0.5%, and Japan’s Nikkei down 1.2%.
European equities were mixed, with Germany’s DAX up 0.4%, Britain’s FTSE 100 down 0.1%, and the Euro Stoxx 50 up 0.3%.
US stocks are set to open slightly lower. Futures underlying the Dow Jones Industrial Average, the S&P 500, and the Nasdaq fell 0.3%.
Oil prices fell, with West Texas Intermediate down 0.6% at $37.75, and Brent crude down 0.3% at $40.19.
The benchmark 10-year Treasury yield fell to 0.66%.
Gold fell 0.2% to $1,771 per ounce.
Read more: A CEO overseeing $147 million outlines his 4-part strategy for identifying which stocks to buy – and shares 2 he sees primed to explode higher right now

Rope Market Size Worth $2.69 Billion by 2027 | CAGR: 8.5%: Grand View Research, Inc.

SAN FRANCISCO, June 25, 2020 /PRNewswire/ — The global rope market size is anticipated to reach USD 2.69 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.5% from 2020 to 2027. Growing awareness related to diverse application of ropes across the end-use industries is likely to drive the market over the forecast period. Increasing application of synthetic rope replacing steel wires across various industries is expected to fuel the market demand over the forecast period.
Key suggestions from the report:
The industrial end-user segment accounted for the largest share of 45.5% in 2019 and is expected to witness the highest growth over the forecast period
By product, synthetic rope held a major share of about 32.0% in 2019 and is expected to maintain its lead in the next few years
APAC is expected to emerge as the fastest growing regional market in the forecast period
The market is characterized by intense competition due to presence of a number of domestic and international players.
Read 80 page research report with ToC on “Rope Market Size, Share & Trends Analysis Report By Product (Synthetic, Steel, Cotton), By End User (Commercial, Residential, Industrial), By Region, And Segment Forecasts, 2020 – 2027” at:
In addition, consumers are increasingly investing in home improvement or home remodeling projects to revamp their traditional household structure, which is likely to contribute to the market growth. According to the American Housing Survey studied by Harvard’s Joint Center for Housing Studies, the home improvement industry size was valued at USD 383.3 billion in 2017.
High demand generated by industrial activities has boosted the application of synthetic rope owing to prominent availability of synthetic fibers, thereby contributing to the global market growth. In addition, wide application of ropes in the maritime industry provides benefits in industrial operations. Rising displacement of hard fiber ropes with synthetic ropes has advanced at a rapid scale in developed countries owing to the commercial utilization of polyolefins fiber. The product also witnesses increasing application in cranes on account of properties, such as bend fatigue durability, high strength-to-weight ratio, and robust spooling capabilities.

Synthetic ropes such as polypropylene and nylon are the commonly preferred types, which are widely used in various industrial sectors, such as construction and marine and fishing. Increasing application of nylon materials in the construction industry is expected to positively impact the demand for synthetic ropes. These braided or twisted wires provide extreme versatility for the strongest option of rope, which provides more balance and does not crook while use in construction business. These ropes are used in the fishing industry as fishing nets, twines, and ropes. These are used in trawling applications on account of better resistance to abrasion, high breaking strength, and high strength-to-weight ratio.
Synthetic ropes are widely used in the marine, fishing, and shipment industries on account of their lightweight properties, reduction in knocking up and preparing for downtime, easy handling, floatable, and avoidance of re-lubing. These ropes assist with great insulation capacity, provide resistance in chemically affected environment, and prevent any absorption.
Grand View Research has segmented the global rope market by product, end user, and region:
Rope Product Outlook (Revenue, USD Million, 2016 – 2027)


Rope End-user Outlook (Revenue, USD Million, 2016 – 2027)


Rope Regional Outlook (Revenue, USD Million, 2016 – 2027)

North America



Asia Pacific


Central & South America

Middle East & Africa

South Africa

List of Key Players of Rope Market

WireCo WorldGroup
Cortland Limited
Southern Ropes
Yale Cordage
LANEX a.s.
Katradis Marine Ropes Ind. S.A.
Dynamica Ropes
Marlow Ropes Ltd.
Van Beelen Industrie en Handel B.V.

Find more research reports on Homecare & Decor Industry, by Grand View Research:
Soap Dispenser Market– Rising concerns about hygiene amongst the consumers across the globe and growing purchasing power of middle-class income groups are likely to drive the market. In addition, increasing sanitation programs by various governments are foreseen to fuel the demand for soap dispensers over the forecast period.
Games And Puzzles Market– Increasing adoption of 3D printing to design innovative board games is expected to contribute to the industry growth significantly. Enhancement in manufacturing technologies has enabled game manufacturers to diversify their product offerings, thus offering new revenue streams.
Bedroom Furniture Market– Shifting consumer preference towards high-end furniture products owing to technological advancements in the home furnishing industry is a key factor driving the market for bedroom furniture.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact: Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: Web:
Follow Us: LinkedIn | Twitter


Markets Accelerates Transformation Journey with Cevitr's RPA Powered Digital Workforce

LONDON, June 25, 2020 /PRNewswire/ — Cevitr, a UK based company, announced a partnership with, an online retailer based in Jersey, to digitally transform their operations. To gain operational efficiency in today’s highly competitive landscape, have deployed Cevitr’s innovative digital workforce solution using Robotic Process Automation (RPA) technology.
Cevitr enables businesses to adopt a digital workforce as a managed service, on an all-inclusive subscription basis – a market first in this space. The Cevitr platform is underpinned by UiPath RPA software hosted on a Microsoft Azure stack. Onogo was able to realise the benefits of the Digital Worker in weeks with zero disruption to existing ways of working.  The solution aided Onogo in coping with the surge of orders during the start of the Covid19 lockdown.
Jo, Cevitr’s Digital Workmate, is now working with the Onogo teams every day on two processes – supplier invoices and warehouse receipting. Jo replicates the entire workflow of an Onogo user right from taking information from an email, processing that in the internal ERP system and their cloud-based work allocation dashboards to finally sending detailed reports to relevant stakeholders. The processes run at different times in the day to ensure that the Onogo teams do not have to deal with a backlog when they sign into work.
The initial processes that have been automated are the start of the automation journey with Onogo and the direct benefits of speed of processing and data quality is accentuated by the indirect benefits of employees being able to focus on business-critical activities to deliver a quality service.
Paul Murphy, CEO of stated that “Established in Jersey since 2008, our goal is to provide the best online value and service through various platforms, including Amazon, where our status is as an Elite Amazon Seller, earned through continuous improvement. We’ve developed bespoke software and business practices to enable us to undertake a global sale every 20 seconds. Complementing this work, with Cevitr’s Digital Worker Jo, has been exciting because it opens up many possibilities as we continue to grow at pace. We are able to focus on our core business whilst relying on Cevitr to focus on the challenge of enabling Jo to take on computer-based tasks and ensuring that it delivers every day.”

Jaideep Mudholkar, Co-Founder and Managing Director Cevitr, said, “Our collaboration with Onogo is exciting as we were able to deliver results to a growing business very quickly – we literally went from discussion of a process to automation in a matter of 3 to 4 weeks. Onogo have a great team and we are excited to see our Digital Worker Jo working hand in hand with the team to deliver value every day.”
For more information about Cevitr, please visit this webpage. More information on Onogo can be found here.
About Cevitr
Cevitr is a UK based company, offering a Digital Workforce to organisations of all sizes using Robotic Process Automation (RPA). The Digital Workforce is fully trained on end customer systems and are offered on a monthly subscription basis with no upfront investment. The service is all inclusive of software licenses, development, deployment and maintenance to ensure that the customer can gain the benefits of a Digital Workmate in weeks.

Onogo buys high potential products and grows them to leading positions on Amazon and other highly competitive marketplaces. continues to develop new categories & international territories. In 12 years of trading the aim has remained to offer best products at great prices. Onogo epitomises a fantastic service boasting a 98% positive customer feedback score.  One of the natural evolutions of Onogo’s marketplace success is to partner with brands. Onogo have achieved success as an ‘Amazon Marketplace Full Service Provider’. Onogo applies commercial experience, tools and expertise to support continuing success. Onogo are in the top 1000 global sellers on the world’s largest marketplace, Amazon.  
Media Contact:CevitrRamesh MenonCo-Founder and Executive Director+44-(0)

Mitie Group FY Pre-tax Profit Rises; To Buy Interserve's Facility Management Business

(RTTNews) – Mitie Group plc (MTO.L), a provider of facilities management and professional services, on Thursday reported preliminary results for fiscal year 2019/20.
The company’s profit before tax for the year was 65.9 million pounds, up from 28.0 million pounds in the prior year. Basic earnings rose to 25.0 pence from 8.6 pence a year ago.
Adjusted basic earnings per share were 16.7 pence, compared to 17.7 pence per share last year.
Revenue for the year rose 4 percent to 2.17 billion pounds from 2.09 billion pounds in the prior year, with flat organic revenue growth.
The company’s board is recommending no final dividend be paid for the full year, given the need to conserve cash in the COVID-19 situation.

In addition, Mitie Group said it has signed a conditional share purchase agreement to acquire the entire issued share capital of Interserve’s Facility Management business for 271 million pounds.
The consideration at completion of the acquisition comprises the issuance of about 358 million ordinary shares, representing about 23.4 percent of the share capital of Mitie following the rights issue and the issue of the consideration shares and a cash payment of 120 million pounds.
Mitie Group said it expects the acquisition to be accretive to its earnings per share in the first full year following completion, which is currently expected to take place in Q4 2020.
Further, Mitie Group said it proposes to raise gross proceeds of about 201 million pounds by way of a rights issue and has reached an agreement with its lenders for an extension of its revolving credit facility or RCF, providing liquidity of 250 million pounds under the facility through to 16 December 2022.
The company noted that the fully underwritten 201 million pounds rights issue and refinancing will provide it with a strong financial position and sufficient liquidity to trade through the COVID-19 pandemic.

The 11 for 5 issue at a price of 25 pence per new ordinary share represents a discount of 68.8 per cent to the closing price on 24 June 2020.

German GfK Consumer Confidence To Rise In July

(RTTNews) – German consumer sentiment is set to recover next month reflecting the rapid reopening of the economy and society, survey results published by market research group GfK showed Thursday.
The forward-looking consumer sentiment index rose to -9.6 in July from revised -18.6 in June. The score was forecast to rise moderately to -12.
Both economic and income expectations, as well as propensity to buy, increased in June.
The economic expectations index rose 18.9 points to 8.5 points in June. Likewise, the income expectations indicator advanced 12.3 points to 6.6 points.
At the same time, the propensity to buy indicator gained 13.9 points to 19.4 points “The faint light at the end of the tunnel, which was already apparent last month, is apparently getting somewhat brighter,” Rolf Bürkl, GfK consumer expert, said.
“The extensive support provided by the economic stimulus packages, such as the announcement of a temporary reduction in value-added tax (VAT), is certainly a contributing factor,” Bürkl added.

Stock Alert: Cumulus Media Shares Up 31% In Late Trade

(RTTNews) – Shares of Cumulus Media Inc. (CMLS) rose $1.36 or 31.70% to $5.65 in the extended trading session on Wednesday, after the company announced that it has completed the sale of an about 75-acre parcel of land in Bethesda, Maryland to Toll Brothers for $74.1 million, continuing to execute on its commitment to reducing net leverage.
The company noted that the net proceeds from the sale are required to be used to pay down debt, unless otherwise reinvested in the company’s business over the next 12 months.
The stock has been trading in the range of $3.00 – $19.18 for the past one year, and closed Wednesday’s trade at $4.29, down 46 cents or 9.68%. Trading volume rose to 619K shares, versus an average volume of 229K shares.

Sensex, Nifty Open Lower On Weak Global Cues

(RTTNews) – Indian shares opened lower on Thursday, with concerns over a continued surge in coronavirus cases as well as rising global trade and geopolitical tensions denting sentiment.
The benchmark S&P BSE Sensex dropped 192 points, or 0.55 percent, to 34,676 in early trade, while the broader NSE Nifty index was down 52 points, or half a percent, at 10,253.
Karur Vysya Bank surged 5.5 percent after reporting a 40 percent increase in its Q4 net profit.
Reliance Industries gained 1 percent. The Competition Commission has cleared Facebook’s proposed acquisition of 9.99 percent stake in Jio Platform.
Bharti Infratel tumbled 3 percent after its board extended the long stop date for the long pending merger with Indus Towers to 31 August.

State-run oil marketing companies BPCL and HPCL rose about 1 percent as oil extended losses after falling more than 5 percent in the previous session.
Apollo Hospitals Enterprises gained 1.4 percent, Bank of India edged up marginally and Engineers India soared as much as 8.7 percent before unveiling their March quarterly earnings.

1 128 129 130 131 132 226